^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Promacta (eltrombopag)

    i
    Other names: SB-497115, SB-497115-GR, 497115, ETB-115, SB497115, SB 497115, SB497115GR, SB 497115 GR, ETB115, ETB 115
    Company:
    GSK, Novartis, Royalty
    Drug class:
    Thrombopoietin receptor agonist
    Related drugs:
    6d
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals | Trial completion date: Aug 2030 --> Mar 2030 | Trial primary completion date: Dec 2028 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    10d
    Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes (clinicaltrials.gov)
    P2, N=174, Recruiting, Associazione Qol-one | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Promacta (eltrombopag)
    22d
    rhTPO Dose Escalation vs Eltrombopag Switch in ITP (clinicaltrials.gov)
    P=N/A, N=112, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New trial
    |
    Promacta (eltrombopag)
    28d
    Severe aplastic anemia concurrent with lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: A case report. (PubMed, Intern Med)
    Treatment prioritized AA with cyclosporine and eltrombopag. Subsequently, the LPL/WM was treated with rituximab monotherapy...Although AA is a diagnosis of exclusion, its coexistence with lymphoma is rare. This case highlights the diagnostic and therapeutic complexity of AA and LPL/WM overlap and suggests that prioritizing the treatment of AA may lead to better outcomes.
    Journal
    |
    MYD88 (MYD88 Innate Immune Signal Transduction Adaptor)
    |
    Rituxan (rituximab) • Promacta (eltrombopag) • cyclosporine
    1m
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=80, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Active, not recruiting --> Recruiting | N=39 --> 80
    Enrollment open • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    2ms
    CETB115G1401: Revolade Tablets Specified Drug-use Survey (clinicaltrials.gov)
    P=N/A, N=10, Recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2029 --> Oct 2028 | Trial primary completion date: Mar 2029 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    Promacta (eltrombopag)
    2ms
    VAY2EXPLORE: A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) (clinicaltrials.gov)
    P2, N=164, Not yet recruiting, Novartis Pharmaceuticals
    New P2 trial
    |
    Promacta (eltrombopag) • Nplate (romiplostim) • ianalumab (VAY736)
    2ms
    A Study of the Safety and Effectiveness of Eltrombopag in Combination With Immunosuppressive Therapy (IST) in Korean Pediatric Patients With Treatment Naïve Severe Aplastic Anemia (clinicaltrials.gov)
    P=N/A, N=13, Completed, Novartis Pharmaceuticals
    New trial
    |
    Promacta (eltrombopag)
    3ms
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=39, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Recruiting --> Active, not recruiting | N=80 --> 39
    Enrollment closed • Enrollment change
    |
    Promacta (eltrombopag) • cyclosporine
    4ms
    20-H-0033: Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA) (clinicaltrials.gov)
    P2, N=80, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: May 2028 --> Dec 2033
    Trial completion date
    |
    Promacta (eltrombopag) • cyclosporine
    4ms
    TQZ3469-BE-01: Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State (clinicaltrials.gov)
    P=N/A, N=36, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Initiation date: Mar 2020 --> Mar 2023
    Trial initiation date
    |
    Promacta (eltrombopag)
    4ms
    The Use of Eltrombopag Post HSCT in BMFD (clinicaltrials.gov)
    P2/3, N=118, Completed, The First Affiliated Hospital of Soochow University | Recruiting --> Completed | Trial completion date: Jul 2027 --> Oct 2025
    Trial completion • Trial completion date
    |
    Promacta (eltrombopag)